NASDAQ:AUTL - Autolus Therapeutics Stock Price, Forecast & News

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

Autolus Therapeutics Ltd - (NASDAQ:AUTL) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.26. The firm earned $0.30 million during the quarter, compared to analysts' expectations of $2 million. Autolus Therapeutics had a negative net margin of 3,576.93% and a negative return on equity of 39.54%. View Autolus Therapeutics' Earnings History.

Autolus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Autolus Therapeutics.

3 analysts have issued twelve-month price targets for Autolus Therapeutics' stock. Their forecasts range from $24.00 to $26.00. On average, they expect Autolus Therapeutics' share price to reach $25.00 in the next twelve months. This suggests a possible upside of 97.6% from the stock's current price. View Analyst Price Targets for Autolus Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Autolus Therapeutics.

Headlines about AUTL stock have been trending somewhat negative this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Autolus Therapeutics earned a news sentiment score of -1.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Autolus Therapeutics.

Autolus Therapeutics saw a drop in short interest in the month of November. As of November 29th, there was short interest totalling 1,180,000 shares, a drop of 10.6% from the November 14th total of 1,320,000 shares. Based on an average daily trading volume, of 104,700 shares, the days-to-cover ratio is currently 11.3 days. Approximately 2.6% of the shares of the stock are sold short. View Autolus Therapeutics' Current Options Chain.

Some companies that are related to Autolus Therapeutics include Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Editas Medicine (EDIT), Regenxbio (RGNX), Fate Therapeutics (FATE), Alector (ALEC), Coherus Biosciences (CHRS), SpringWorks Therapeutics (SWTX), Orchard Therapeutics (ORTX), Krystal Biotech (KRYS), Cortexyme (CRTX), Rubius Therapeutics (RUBY), Sangamo Therapeutics (SGMO), Aerie Pharmaceuticals (AERI) and NanoString Technologies (NSTG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Autolus Therapeutics investors own include Portola Pharmaceuticals (PTLA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), Crispr Therapeutics (CRSP), GW Pharmaceuticals PLC- (GWPH), Nightstar Therapeutics (NITE), Uxin (UXIN), Cara Therapeutics (CARA), Galmed Pharmaceuticals (GLMD) and Ligand Pharmaceuticals (LGND).

(AUTL) raised $125 million in an initial public offering on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

Autolus Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (3.48%), Granahan Investment Management Inc. MA (0.76%), Point72 Asset Management L.P. (0.19%), State Street Corp (0.03%) and Barclays PLC (0.01%).

AUTL stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Point72 Asset Management L.P., Granahan Investment Management Inc. MA, State Street Corp and Barclays PLC.

Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AUTL stock can currently be purchased for approximately $12.65.

Autolus Therapeutics has a market capitalization of $507.90 million and generates $1.41 million in revenue each year. The company earns $-12,860,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. View Additional Information About Autolus Therapeutics.

The official website for Autolus Therapeutics is http://www.autolus.com/.

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 44-20-3829-6230 or via email at [email protected]